Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma

Yong Wook Jung, Sang Wun Kim, Sunghoon Kim, Jae-Hoon Kim, Namhoon Cho, Jae Wook Kim, YoungTae Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy. Study design: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study. COX-1 and -2 expression and clinicopathologic features were evaluated. COX-1 and -2 expression was determined by immunohistochemistry. Results: The prevalence of COX-1 and -2 expression was similar at 73.9%. Significant COX-1 and -2 expression was 47.8 and 60.9%, respectively. COX-2 expression was associated with poor response to treatment and cancer-related death (P = 0.043 and 0.012, respectively). Poor survival was identified in patients who showed high COX-2 expression (P = 0.016). There was no correlation between COX-1 expression and patient prognosis. Conclusion: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma. However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.

Original languageEnglish
Pages (from-to)62-66
Number of pages5
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume148
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Cyclooxygenase 1
Cyclooxygenase 2
Adenocarcinoma
Chemoradiotherapy
Second Primary Neoplasms
Prostaglandin-Endoperoxide Synthases
Immunohistochemistry
Survival

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

@article{16aae3e777244bd3995b104cd6ffc9e7,
title = "Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma",
abstract = "Objective: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy. Study design: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study. COX-1 and -2 expression and clinicopathologic features were evaluated. COX-1 and -2 expression was determined by immunohistochemistry. Results: The prevalence of COX-1 and -2 expression was similar at 73.9{\%}. Significant COX-1 and -2 expression was 47.8 and 60.9{\%}, respectively. COX-2 expression was associated with poor response to treatment and cancer-related death (P = 0.043 and 0.012, respectively). Poor survival was identified in patients who showed high COX-2 expression (P = 0.016). There was no correlation between COX-1 expression and patient prognosis. Conclusion: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma. However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.",
author = "Jung, {Yong Wook} and Kim, {Sang Wun} and Sunghoon Kim and Jae-Hoon Kim and Namhoon Cho and Kim, {Jae Wook} and YoungTae Kim",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.ejogrb.2009.09.011",
language = "English",
volume = "148",
pages = "62--66",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma. / Jung, Yong Wook; Kim, Sang Wun; Kim, Sunghoon; Kim, Jae-Hoon; Cho, Namhoon; Kim, Jae Wook; Kim, YoungTae.

In: European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 148, No. 1, 01.01.2010, p. 62-66.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma

AU - Jung, Yong Wook

AU - Kim, Sang Wun

AU - Kim, Sunghoon

AU - Kim, Jae-Hoon

AU - Cho, Namhoon

AU - Kim, Jae Wook

AU - Kim, YoungTae

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy. Study design: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study. COX-1 and -2 expression and clinicopathologic features were evaluated. COX-1 and -2 expression was determined by immunohistochemistry. Results: The prevalence of COX-1 and -2 expression was similar at 73.9%. Significant COX-1 and -2 expression was 47.8 and 60.9%, respectively. COX-2 expression was associated with poor response to treatment and cancer-related death (P = 0.043 and 0.012, respectively). Poor survival was identified in patients who showed high COX-2 expression (P = 0.016). There was no correlation between COX-1 expression and patient prognosis. Conclusion: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma. However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.

AB - Objective: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy. Study design: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study. COX-1 and -2 expression and clinicopathologic features were evaluated. COX-1 and -2 expression was determined by immunohistochemistry. Results: The prevalence of COX-1 and -2 expression was similar at 73.9%. Significant COX-1 and -2 expression was 47.8 and 60.9%, respectively. COX-2 expression was associated with poor response to treatment and cancer-related death (P = 0.043 and 0.012, respectively). Poor survival was identified in patients who showed high COX-2 expression (P = 0.016). There was no correlation between COX-1 expression and patient prognosis. Conclusion: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma. However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=72049113571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049113571&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2009.09.011

DO - 10.1016/j.ejogrb.2009.09.011

M3 - Article

C2 - 19836124

AN - SCOPUS:72049113571

VL - 148

SP - 62

EP - 66

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -